Backed by some of the biggest names in biotech, Norbert Bischofberger gets his megaround for platform tech out of MIT
A little over a year ago when I reported on Norbert Bischofberger’s jump from the CSO job at giant Gilead to a tiny upstart called Kronos, I noted that with his connections in biotech finance, that $18 million launch round he was starting off with could just as easily have been $100 million or more.
With his first anniversary now behind him, Bischofberger has that mega-round in the bank.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.